Alle Fälle anzeigen
ACT 16120/2024
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerletzungKategorieHauptverletzungsklage
- Parteien
- Kläger
- Sanofi SA
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (McDermott Will & Schulte)Beklagte- Zentiva Pharma GmbH
- Zentiva France
- Zentiva, k.s.
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Accord Healthcare S.L.U.
- Accord Healthcare B.V.
- Accord Healthcare GmbH (DE)
- Accord Healthcare Italia Srl
Vertreter: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing) - Division
- Munich LD
- Richter
- Matthias Zigann · Presiding judge and judge-rapporteur
- Technology
- Pharmaceuticals · Oncology · Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 15. Sept. 2025
Entscheidungen
- 2025-09-15Infringement Action
Munich Local Division order (judge-rapporteur Zigann) following the second interim conference in consolidated infringement proceedings by Sanofi entities against Zentiva, STADA, Dr. Reddy's and Accord Healthcare groups concerning EP 2 493 466 (insulin glargine). The order confirms the oral hearing dates (14-17 October 2025), orders all four counterclaims to be heard together with separate handling of each infringement action, and gives organisational directions for the hearing.
Rechtsfragen:Oral hearing scheduling (R. 105.5 RoP)Coordination of joint counterclaims for revocation with multiple infringement actionsInsulin glargine / pharmaceutical patent
Dokumente
- AC64EA303FA916C1FEAE409E93F21FF7_en.pdf2025-09-15ENGLISH